A study from the Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, USA; and College of Physicians and Surgeons, Columbia University, New York, USA shows that “A targetable GATA2-IGF2 axis confers aggressiveness in lethal prostate cancer.” This study was published in the 9 Feb 2015 issue of the Journal “Cancer cell” (the no.1 journal in cancer biology with an impact factor of 23.893) by Prof Domingo-Domenech J, Vidal SJ, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: MiRNA-based therapy for Prostate cancer: MiRNA-100 suppresses GATA2-IGF2 axis and halts the progression of prostate cancer.
Significance: Given that prostate cancer is/had: (1) one of the most frequently diagnosed cancer in males; (2) the sixth leading cause of cancer death in males worldwide; and (3) caused 256,000 deaths in 2010, there is an urgent need to find an effective therapy for prostate cancer. This study suggests, for the first time, that MiRNA-100, by decreasing the expression of its target gene IGF2, it may inhibit the GATA2-IGF2 axis in aggressive prostate cancer. Thereby, it may inhibit the progression of aggressive prostate cancer. Thus, pharmacological formulations encompassing “MiRNA-100 or its activators” may be used to inhibit the progression of prostate cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, MiRNA-based therapy for Prostate cancer: MiRNA-100 suppresses GATA2-IGF2 axis and halts the progression of prostate cancer, 10/April/2015, 14.48, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
